As part of our ongoing aim to bring you reports of interesting new studies, we have added a review of a recent study which examines bleeding risk with rivaroxaban vs vitamin K antagonists in patients aged ≥80 years.
Independent expert commentary is provided by Dr Christopher Hammett, an Interventional Cardiologist at the Royal Brisbane and Women’s Hospital, Brisbane Queensland.
Please login below to download this issue (PDF)